Join the Tardive Dyskinesia group to help and get support from people like you.
Tardive Dyskinesia News
Related terms: Tardive, Dyskinesia
Neurocrine Biosciences Announces U.S. FDA Approval of Ingrezza Sprinkle (valbenazine) Capsules
SAN DIEGO, April 30, 2024 /PRNewswire/ – Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration has approved Ingrezza Sprinkle (valbenazine) capsules, a...
Tardive Dyskinesia Impact Scale Captures Relevant Info About Condition
FRIDAY, Jan. 19, 2024 – The Tardive Dyskinesia Impact Scale (TDIS) patient-reported outcome measure captures information about the impact of TD, according to a study published online Jan. 4 in the...
Tardive Dyskinesia Impacts Patients and Caregivers
FRIDAY, Dec. 8, 2023 – Tardive dyskinesia (TD) poses a substantial burden for both caregivers and patients, according to a study published online Nov. 28 in the Journal of Patient-Reported Outcomes. ...
Tardive Dyskinesia Has Considerable Impact on Multiple Domains
TUESDAY, Aug. 22, 2023 – Tardive dyskinesia (TD) has a considerable impact on physical, psychological, social, and professional lives, according to a study published in the May/June issue of the...
One-Hour Training Improves Documentation to Diagnose, Treat Tardive Dyskinesia
TUESDAY, July 18, 2023 – An annual one-hour Abnormal Involuntary Movement Score (AIMS) training session improves documentation to recognize and treat tardive dyskinesia in the psychiatry outpatient...
Sex Differences Seen in Cognitive Impairment for Tardive Dyskinesia in Schizophrenia
FRIDAY, May 19, 2023 – For schizophrenia patients with tardive dyskinesia (TD), there may be sex differences in cognitive impairment, with a protective effect suggested by female gender, according...
Teva Announces FDA Approval of Austedo XR (deutetrabenazine) Extended-Release Tablets, a New Once-Daily Formulation of Austedo
New once-daily Austedo XR regimen now approved in 6, 12, and 24 mg tablet strengths Austedo is the only vesicular monoamine transporter 2 (VMAT2) inhibitor approved for both tardive dyskinesia (TD)...
Teva Announces FDA Approval of Austedo (deutetrabenazine) Tablets for the Treatment of Tardive Dyskinesia in Adults
JERUSALEM--(BUSINESS WIRE) August 30, 2017 --Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved Austedo...
FDA Approves Gocovri (amantadine) for the Treatment of Dyskinesia in Parkinson's Disease Patients
EMERYVILLE, Calif., Aug. 24, 2017 (GLOBE NEWSWIRE) – Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the U.S. Food and Drug Administration (FDA) has approved Gocovri (amantadine)...
Neurocrine Announces FDA Approval of Ingrezza (valbenazine) as the First and Only Approved Treatment for Adults with Tardive Dyskinesia (TD)
SAN DIEGO, April 11, 2017 /PRNewswire/ – Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that the U.S. Food and Drug Administration (FDA) has approved Ingrezza (valbenazine) capsules for...
Ask a question
To post your own question to this support group, sign in or create an account.